A Common ADHD Med Might Not Raise Psychosis Risk After All
By Ed Cara
Published on March 25, 2026.
A study by scientists in the UK has found that methylphenidate, the active ingredient in brand-name drugs like Ritalin, does not raise the risk of developing psychotic disorders later in life. The researchers studied the mental health outcomes of people diagnosed with ADHD in Finland. They found no evidence that methyl phenidate itself raised this risk. The study's author, Ian Kelleher, said the findings dispel a common fear about long-term use of stimulants for ADHD. However, he cautioned that further research is needed to address these issues. The findings were published in JAMA Psychiatry.
Related Articles
Neurophet and ALZ-NET sign MoU on Alzheimer’s therapies
South Korean AI company Neurophet and ALZ-NET signed a MoU to enhance imaging infrastructure for Alzheimer's therapies, enhancing quality and quality of care for patients.
Rocket Pharma Wins FDA Approval For KRESLADI — The First Ever Gene Therapy For Severe LAD-I
Rocket Pharmaceuticals secured accelerated FDA approval for KRESLADI, the first-ever gene therapy for severe Leukocyte Adhesion Deficiency-I, with multiple designations and post-marketing milestones.
Yuen: She asked her dates about colonoscopies on ‘Love Is Blind.’ Now she wants you to get one.
Despite the rise in colonoscopies prevalence, stigma remains a barrier to getting a colonoscopy, particularly among younger adults, with multiple factors including insurance costs and cultural sensitivity.